Arax Advisory Partners’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
Other funds holding ENTA
JT
KAM
FCM
DTC
ACM
SSC
Arax Advisory Partners's ENTA Position: Q2 2026 in Review
Arax Advisory Partners increased its Enanta Pharmaceuticals (ENTA) stake by 7,879% in Q2 2026, buying an estimated $95.3K and bringing the position to 7,181 shares worth $105K. The position accounts for ﹤0.01% of the portfolio, ranked #2697.
Arax Advisory Partners first reported a position in ENTA in Q2 2024 and has held it in 6 quarters since. 123 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.
- Arax Advisory Partners held 7,181 shares of Enanta Pharmaceuticals worth $105K as of Q2 2026.
- Arax Advisory Partners bought 7,091 Enanta Pharmaceuticals shares in Q2 2026, an estimated $95.3K.
- Enanta Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #2697 holding.
- Arax Advisory Partners first reported a position in Enanta Pharmaceuticals in Q2 2024 and has held it in 6 quarters since.
- 123 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.
Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.